European Lung Cancer Congress 2026
Trials whose public commentary places their results at European Lung Cancer Congress 2026, Mar 25–28, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
7 trials: 2 with reports and 5 with no report yet. Organised by European Society for Medical Oncology (ESMO); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Advanced solid tumors · 1 | |||||||
| KANDLELIT-001 calderasib (MK-1084); calderasib (MK-1084) plus pembrolizumab; calderasib (MK-1084) plus cetuximab placed at European Lung Cancer Congress 2026 by 4 sources NCT05067283 · Merck Sharp & Dohme LLC | KRAS G12C-mutant advanced solid tumors | Phase 1 | 52 | 18 | Focused | Oct 31, 2026 | Preview |
| Non-small cell lung cancer · 1 | |||||||
| ROSETTA Lung-02 pumitamig (BNT327) placed at European Lung Cancer Congress 2026 by 2 sources NCT06712316 · BioNTech SE | first-line non-small cell lung cancer | Phase 2/Phase 3 | 146 | 31 | Focused | Nov 2, 2026 | Preview |
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Non-small cell lung cancer · 5 | |||||||
| LATIFY ceralasertib plus durvalumab placed at European Lung Cancer Congress 2026 by 4 sources NCT05450692 · AstraZeneca DeepView → | advanced or metastatic non-small cell lung cancer | Phase 3 | Deep | View | |||
| PRESERVE-003 gotistobart placed at European Lung Cancer Congress 2026 by 4 sources NCT05671510 · OncoC4, Inc. DeepView → | metastatic squamous NSCLC after PD-(L)1 progression | Phase 3 | Deep | View | |||
| ADEPPT adagrasib placed at European Lung Cancer Congress 2026 by 3 sources NCT05673187 · ETOP IBCSG Partners Foundation FocusedView → | KRASG12C-mutant NSCLC, elderly or poor performance status | Phase 2 | Focused | View | |||
| KEYNOTE-671 pembrolizumab placed at European Lung Cancer Congress 2026 by 3 sources NCT03425643 · Merck Sharp & Dohme LLC DeepView → | resectable stage II–IIIB non-small cell lung cancer | Phase 3 | Deep | View | |||
| TOP osimertinib plus pemetrexed plus carboplatin placed at European Lung Cancer Congress 2026 by 3 sources NCT04695925 · Li Zhang, MD StandardView → | untreated advanced nonsquamous NSCLC with EGFR/TP53 mutations | Phase 3 | Standard | View | |||